Welcome from the Division Chief
Welcome to the website for the Division of Infectious Diseases & HIV Medicine at Case Western Reserve University. We are incredibly proud of our tradition and accomplishments in contributing to the advancement of treatment of infectious diseases locally, nationally and worldwide.
Our core mission is to heal, to teach and to discover. Facing the challenges of emerging and re-emerging infectious diseases at home and across the globe; we pride ourselves on delivering the highest quality of care for our patients, providing exceptional fellowship training to the next generation of Infectious Diseases physicians and continuing to make scientific breakthroughs through our world renowned research.
Pilot Research Support from the IDII
February 15, 2013 - The Infectious Diseases & Immunology Institute (IDII) at Case Western Reserve University will provide seed money to young faculty to foster interdisciplinary research in infectious diseases and immunology. Investigators in the basic science and clinical departments in the School of Medicine and Hospital System as well as in other departments throughout the University are eligible. Grants, not to exceed $10,000 direct costs each, will be awarded to young investigators who intend to gather preliminary data to be used in seeking future independently funded awards. Research activity and themes should be multidisciplinary and involve investigators across the IDII. In the first year of funding, up to four grants will be awarded. Read more...
AstraZeneca & CWRU Initiate New Tuberculosis Drug Trial
December 12, 2012 - Case Western Reserve University School of Medicine and AstraZeneca, a global biopharmaceutical company, today announced the first patient enrolled in a Phase 2a trial to assess the effectiveness of AZD5847, a new test drug for patients with tuberculosis (TB), including patients with HIV co-infection. Read more...
HIV Immune Failure Linked to Microbial Exposure
Even with effective antiretroviral therapy, many patients with HIV infection cannot restore adequate levels of CD4+ T-cells - important immune cells that are targeted and depleted by HIV. Dr. Michael Lederman has found in his study that in such instances of immune failure, T-cells remained activated and this was associated with inflammation and evidence of systemic exposure to microbial products from the damaged gut. The findings suggest that even with the proper use of antiretroviral therapies to control HIV, persistent inflammation is linked to a failure to normalize immune defenses, placing these patients at greater risk for complications. The article entitled "Immunologic Failure Despite Suppressive Antiretroviral Therapy is Related to Activation and Turnover of Memory CD4 Cells" was published in The Journal of Infectious Diseases.
Insights for providing TB therapies
One-third of the world's population is infected with Mycobacterium tuberculosis, the bacteria that causes most cases of TB. While most recover from TB infection, the bacteria can lie dormant, hiding in the body's immune cells for years before reactivating. Clifford V. Harding, MD, PhD, W. Henry Boom, MD, and colleagues recently discovered how the TB bacterium is able to survive within the immune system and inhibit the ability of macrophages to stimulate infection fighting responses. The discovery can provide insights for designing TB therapies.